肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

肝癌转化治疗中国专家共识（2021版）

2021-06-24 中国抗癌协会肝癌专业委员会 中国实用外科杂志

肝癌原发性肝癌

国内许多研究中心已积累了肝癌转化治疗经验。初步研究结果显示，转化治疗是改善中晚期肝癌病人生存的重要途径。但转化治疗及其相关领域仍存在许多亟待解决的临床和科学问题。为了总结既往经验、梳理问题，由中国抗癌

中文标题：

肝癌转化治疗中国专家共识（2021版）

发布机构：

中国抗癌协会肝癌专业委员会

发布日期：

2021-06-24

简要介绍：

国内许多研究中心已积累了肝癌转化治疗经验。初步研究结果显示，转化治疗是改善中晚期肝癌病人生存的重要途径。但转化治疗及其相关领域仍存在许多亟待解决的临床和科学问题。为了总结既往经验、梳理问题，由中国抗癌协会肝癌专业委员会转化治疗协作组发起，基于国内外该领域研究获得的初步经验和研究结果，结合符合我国国情的临床实践，制订《肝癌转化治疗中国专家共识（2021版）》。

相关资料下载：
[AttachmentFileName(sort=1, fileName=肝癌转化治疗中国专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=0d71d1c002125101, title=肝癌转化治疗中国专家共识（2021版）, enTitle=, guiderFrom=中国实用外科杂志, authorId=0, author=, summary=国内许多研究中心已积累了肝癌转化治疗经验。初步研究结果显示，转化治疗是改善中晚期肝癌病人生存的重要途径。但转化治疗及其相关领域仍存在许多亟待解决的临床和科学问题。为了总结既往经验、梳理问题，由中国抗癌, cover=, journalId=0, articlesId=null, associationId=137, associationName=中国抗癌协会肝癌专业委员会, associationIntro=为中国抗癌协会的直属二级机构，中国抗癌协会肝癌专业委员会是我国肝癌学术领域最权威的机构，汇聚了全国各地肝癌研究领域的领先专家。致力于国内肝癌知识和技术的普及和推广。, copyright=0, guiderPublishedTime=Thu Jun 24 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>国内许多研究中心已积累了肝癌转化治疗经验。初步研究结果显示，转化治疗是改善中晚期肝癌病人生存的重要途径。但转化治疗及其相关领域仍存在许多亟待解决的临床和科学问题。为了总结既往经验、梳理问题，由中国抗癌协会肝癌专业委员会转化治疗协作组发起，基于国内外该领域研究获得的初步经验和研究结果，结合符合我国国情的临床实践，制订《肝癌转化治疗中国专家共识（2021版）》。</p>, tagList=[TagDto(tagId=429, tagName=肝癌), TagDto(tagId=1097, tagName=原发性肝癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8961, appHits=585, showAppHits=0, pcHits=2587, showPcHits=8376, likes=3, shares=84, comments=38, approvalStatus=1, publishedTime=Sat Jul 03 09:20:49 CST 2021, publishedTimeString=2021-06-24, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Sat Jul 03 09:20:12 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 14:53:41 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=肝癌转化治疗中国专家共识.pdf)])
肝癌转化治疗中国专家共识.pdf
下载请点击：
评论区 (31)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1186999, encodeId=19da118699945, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:05:06 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182802, encodeId=ce9b11828023b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqCoDMNz4hWhaHjOhjBibyibib5RqwGBz8AfNlDoVWV7BpLc7UDz0JneHUJAxG6fa1XvyIw7OdOtndVw/132, createdBy=50c22041566, createdName=Nature12, createdTime=Mon Jan 10 12:33:28 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085072, encodeId=452210850e270, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cca5577874, createdName=ms2000002042000994, createdTime=Tue Dec 28 11:48:11 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079829, encodeId=ca7b10e982918, content=好的文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59bb5317963, createdName=148a0bacm63暂无昵称, createdTime=Tue Dec 14 09:12:20 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063064, encodeId=d5c51063064ba, content=可以, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11372528848, createdName=124f81f4m99暂无昵称, createdTime=Sat Oct 23 00:19:50 CST 2021, time=2021-10-23, status=1, ipAttribution=)]
    2022-01-21 未来将来

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1186999, encodeId=19da118699945, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:05:06 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182802, encodeId=ce9b11828023b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqCoDMNz4hWhaHjOhjBibyibib5RqwGBz8AfNlDoVWV7BpLc7UDz0JneHUJAxG6fa1XvyIw7OdOtndVw/132, createdBy=50c22041566, createdName=Nature12, createdTime=Mon Jan 10 12:33:28 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085072, encodeId=452210850e270, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cca5577874, createdName=ms2000002042000994, createdTime=Tue Dec 28 11:48:11 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079829, encodeId=ca7b10e982918, content=好的文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59bb5317963, createdName=148a0bacm63暂无昵称, createdTime=Tue Dec 14 09:12:20 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063064, encodeId=d5c51063064ba, content=可以, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11372528848, createdName=124f81f4m99暂无昵称, createdTime=Sat Oct 23 00:19:50 CST 2021, time=2021-10-23, status=1, ipAttribution=)]
    2022-01-10 Nature12

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1186999, encodeId=19da118699945, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:05:06 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182802, encodeId=ce9b11828023b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqCoDMNz4hWhaHjOhjBibyibib5RqwGBz8AfNlDoVWV7BpLc7UDz0JneHUJAxG6fa1XvyIw7OdOtndVw/132, createdBy=50c22041566, createdName=Nature12, createdTime=Mon Jan 10 12:33:28 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085072, encodeId=452210850e270, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cca5577874, createdName=ms2000002042000994, createdTime=Tue Dec 28 11:48:11 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079829, encodeId=ca7b10e982918, content=好的文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59bb5317963, createdName=148a0bacm63暂无昵称, createdTime=Tue Dec 14 09:12:20 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063064, encodeId=d5c51063064ba, content=可以, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11372528848, createdName=124f81f4m99暂无昵称, createdTime=Sat Oct 23 00:19:50 CST 2021, time=2021-10-23, status=1, ipAttribution=)]
    2021-12-28 ms2000002042000994

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1186999, encodeId=19da118699945, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:05:06 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182802, encodeId=ce9b11828023b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqCoDMNz4hWhaHjOhjBibyibib5RqwGBz8AfNlDoVWV7BpLc7UDz0JneHUJAxG6fa1XvyIw7OdOtndVw/132, createdBy=50c22041566, createdName=Nature12, createdTime=Mon Jan 10 12:33:28 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085072, encodeId=452210850e270, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cca5577874, createdName=ms2000002042000994, createdTime=Tue Dec 28 11:48:11 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079829, encodeId=ca7b10e982918, content=好的文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59bb5317963, createdName=148a0bacm63暂无昵称, createdTime=Tue Dec 14 09:12:20 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063064, encodeId=d5c51063064ba, content=可以, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11372528848, createdName=124f81f4m99暂无昵称, createdTime=Sat Oct 23 00:19:50 CST 2021, time=2021-10-23, status=1, ipAttribution=)]
    2021-12-14 148a0bacm63暂无昵称

    好的文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1186999, encodeId=19da118699945, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:05:06 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182802, encodeId=ce9b11828023b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqCoDMNz4hWhaHjOhjBibyibib5RqwGBz8AfNlDoVWV7BpLc7UDz0JneHUJAxG6fa1XvyIw7OdOtndVw/132, createdBy=50c22041566, createdName=Nature12, createdTime=Mon Jan 10 12:33:28 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085072, encodeId=452210850e270, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cca5577874, createdName=ms2000002042000994, createdTime=Tue Dec 28 11:48:11 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079829, encodeId=ca7b10e982918, content=好的文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59bb5317963, createdName=148a0bacm63暂无昵称, createdTime=Tue Dec 14 09:12:20 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063064, encodeId=d5c51063064ba, content=可以, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11372528848, createdName=124f81f4m99暂无昵称, createdTime=Sat Oct 23 00:19:50 CST 2021, time=2021-10-23, status=1, ipAttribution=)]
    2021-10-23 124f81f4m99暂无昵称

    可以

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

原发性肝癌的分层筛查与监测指南（2020版）

中华预防医学会(CPMA,Chinese Preventive Medicine Association) · 2021-01-27

中国肝癌多学科综合治疗专家共识

中国抗癌协会肝癌专业委员会(CSLC,Chinese Society of Liver Cancer) · 2020-12-20

影像引导肝癌的冷冻消融治疗专家共识（2020 版）

亚洲冷冻治疗学会 · 2020-05-05

中国肝癌一级预防专家共识（2018）

中华预防医学会(CPMA,Chinese Preventive Medicine Association) · 2018-09-01

【指南专题】3.18全国护肝日，踢开肝癌，最新肝癌指南汇总

暂未更新 · 2017-03-17

《原发性肝癌规范化病理诊断指南（2015 年版）》解读

中国抗癌协会肝癌专业委员会(CSLC,Chinese Society of Liver Cancer) · 2016-07-30